TScan Therapeutics (TScan Therapeutics) Sloan Ratio % : -2.49% (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is TScan Therapeutics Sloan Ratio %?

Richard Sloan from the University of Michigan was first to document what is referred to as the "accrual anomaly". His 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones.

TScan Therapeutics's Sloan Ratio for the quarter that ended in Mar. 2024 was -2.49%.

As of Mar. 2024, TScan Therapeutics has a Sloan Ratio of -2.49%, indicating the company is in the safe zone and there is no funny business with accruals.

TScan Therapeutics Sloan Ratio % Historical Data

The historical data trend for TScan Therapeutics's Sloan Ratio % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TScan Therapeutics Sloan Ratio % Chart

TScan Therapeutics Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Sloan Ratio %

0.22

-37.93

5.31

2.26

12.09

TScan Therapeutics Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Sloan Ratio %	Get a 7-Day Free Trial													1.08	0.03	10.06	12.09	-2.49

Competitive Comparison of TScan Therapeutics's Sloan Ratio %

For the Biotechnology subindustry, TScan Therapeutics's Sloan Ratio %, along with its competitors' market caps and Sloan Ratio % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TScan Therapeutics's Sloan Ratio % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TScan Therapeutics's Sloan Ratio % distribution charts can be found below:

* The bar in red indicates where TScan Therapeutics's Sloan Ratio % falls into.

TScan Therapeutics Sloan Ratio % Calculation

Earnings contain a lot of non cash earnings which is called accruals. The Sloan ratio is a way to identify firms with low non-cash or accrual-derived earnings relative to their cash flow.

TScan Therapeutics's Sloan Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Sloan Ratio	=	(Net Income (A: Dec. 2023 )	-	Cash Flow from Operations (A: Dec. 2023 )
	-	Cash Flow from Investing (A: Dec. 2023 ))	/	Total Assets (A: Dec. 2023 )
	=	(-89.218	-	-61.358
	-	-60.759)	/	272.149
	=	12.09%

TScan Therapeutics's Sloan Ratio for the quarter that ended in Mar. 2024 is calculated as

Sloan Ratio	=	(Net Income (TTM)	-	Cash Flow from Operations (TTM))
	-	Cash Flow from Investing (TTM))	/	Total Assets (Q: Mar. 2024 )
	=	(-96.797	-	-67.038
	-	-23.758)	/	240.832
	=	-2.49%

TScan Therapeutics's Net Income for the trailing twelve months (TTM) ended in Mar. 2024 was -24.045 (Jun. 2023 ) + -22.997 (Sep. 2023 ) + -19.613 (Dec. 2023 ) + -30.142 (Mar. 2024 ) = $-96.80 Mil.
TScan Therapeutics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2024 was -22.022 (Jun. 2023 ) + 8.017 (Sep. 2023 ) + -23.766 (Dec. 2023 ) + -29.267 (Mar. 2024 ) = $-67.04 Mil.
TScan Therapeutics's Cash Flow from Investing for the trailing twelve months (TTM) ended in Mar. 2024 was -0.42 (Jun. 2023 ) + -61.414 (Sep. 2023 ) + 1.913 (Dec. 2023 ) + 36.163 (Mar. 2024 ) = $-23.76 Mil.

TScan Therapeutics (NAS:TCRX) Sloan Ratio % Explanation

A former University of Michigan researcher, Richard Sloan's 1996 paper found that shares of companies with small or negative accruals vastly outperform (+10%) those of companies with large ones. In fact, for the 40-year period between 1962 and 2001, buying the lowest accrual companies and shorting the highest accrual companies resulted in an average annual compounded return of 18%, more than double the S&P 500's 7.4% annual return over the same period.

According to How to Beat the Market with the Sloan Ratio:

If the Sloan Ratio is between -10% and 10%, the company is in the safe zone and there is no funny business with accruals.

If the Sloan Ratio is less than between -25% and -10% on the negative side, and between 10% and 25% on the positive side, this is a warning stage of accrual build up.

If the Sloan Ratio is less than -25% or greater than 25%, and this ratio is consistent over several quarters or even years, be careful. Earnings are highly likely to be made up of accruals.

As of Mar. 2024, TScan Therapeutics has a Sloan Ratio of -2.49%, indicating the company is in the safe zone and there is no funny business with accruals.

TScan Therapeutics Sloan Ratio % Related Terms

Thank you for viewing the detailed overview of TScan Therapeutics's Sloan Ratio % provided by GuruFocus.com. Please click on the following links to see related term pages.

TScan Therapeutics (TScan Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TScan Therapeutics Inc (NAS:TCRX) » Definitions » Sloan Ratio %

Comparable Companies

Traded in Other Exchanges

N/A

Address

830 Winter Street, Waltham, MA, USA, 02451

Website

https://www.tscan.com

TScan Therapeutics Inc is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.

Executives

Timothy J Barberich	director	40 ELM ST, CONCORD MA 01752
Barbara Klencke	director	C/O SIERRA ONCOLOGY, INC., 1820 GATEWAY DRIVE, SUITE 110, SAN MATEO CA 94404
Leiden Dworak	officer: Chief Accounting Officer	C/O TSCAN THERAPEUTICS, INC., 880 WINTER STREET, WALTHAM MA 02451
Lynx1 Capital Management Lp	10 percent owner	151 CALLE DE SAN FRANCISCO, SUITE 200 PMB 1237, SAN JUAN PR 00901-1607
Weston Nichols	10 percent owner	C/O CRINETICS PHARMACEUTICALS, INC., 10222 BARNES CANYON ROAD, BLDG. #2, SAN DIEGO CA 92121
Ecor1 Capital, Llc	10 percent owner	357 TEHAMA STREET #3, SAN FRANCISCO CA 94103
Brian M. Silver	officer: Chief Financial Officer	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
Debora Barton	officer: Chief Medical Officer	C/O TSCAN THERAPEUTICS, INC., 830 WINTER STREET, WALTHAM MA 02451
David P Southwell	director, officer: Chief Executive Officer	C/O INOTEK PHARMACEUTICALS CORPORATION, 91 HARTWELL AVENUE, LEXINGTON MA 02421
Baker Bros. Advisors Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Julian Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014
Baker Bros. Advisors (gp) Llc	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
L.p. 667,	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Baker Brothers Life Sciences Lp	director, 10 percent owner	860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014
Felix Baker	director, 10 percent owner	BAKER BROS. ADVISORS LP, 860 WASHINGTON STREET 3RD FLOOR, NEW YORK NY 10014